Skip to content
value.today
Nutriband Inc. logo

Nutriband Inc.

NTRB
$79 Mmarket cap on Oct 29, 2026+315.2% since Jan 2024
Compare
World rank
#19,642
Revenue
$2 M
For year ending January-2026
Net income
$-8 M
-403.4% margin
SEC filing
Employees
—

Nutriband Inc. in brief

Nutriband Inc. is a listed company in the Biotechnology industry, based in Orlando, Florida, USA. Its market value was $79 M on 29 October 2026, which makes it the 19,642nd largest listed company in the world and the 3,645th largest in the USA on this site. In the year to January 2026 it had sales of $2 M and a net loss of $8 M. Its largest product and service lines by sales in 2026 were Sale of Goods (100%). By market, the largest shares of its 2026 sales came from USA (100%). Its shares trade under the symbol NTRB (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Nutriband Inc.

Nutriband Inc., was incorporated in Nevada in January 2016. Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our development pipeline primarily consists of transdermal products that are based on our proprietary AVERSA™ abuse deterrent transdermal technology that we believe can be incorporated into existing transdermal patches that contain drugs that are susceptible to abuse and misuse such as opioid and stimulant drugs.

The Company’s revenues are based on providing services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics. Pocono Pharmaceuticals provides contract manufacturing services for health, wellness and over-the-counter pharmaceutical customers and 4P Therapeutics performs contract research and development related services for pharmaceutical and medical devices customers. We manage and evaluate our operations, and report our financial results, through these two separate subsidiaries.

From the company's annual report filed with the US SEC: read the report

Nutriband Inc. timeline

2 events, 2016–2024
  1. 2016
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2024
  4. 💰
    Record revenue of $2 million
    FY2024, the highest of the 8 years on record.

Events of Nutriband Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$25 M$50 M$75 M$99 M2020202120222023202420252026

World rank over time

▲ up 363 places since 2020
2020-01-01: #20052#20,05220202021-01-01: #18484#18,48420212022-01-07: #27350#27,35020222022-12-25: #27938#27,93820222023-07-30: #27168#27,16820232024-01-05: #29059#29,05920242026-03-08: #10875#10,87520262026-08-01: #20036#20,03620262026-10-14: #19685#19,68520262026-10-29: #19689#19,6892026

Rank in USA: #3,877 (Jan 2020) · #3,735 (Jan 2021) · #4,930 (Jan 2022) · #5,112 (Dec 2022) · #4,958 (Jul 2023) · #4,375 (Jan 2024) · #2,124 (Mar 2026) · #3,800 (Aug 2026) · #3,620 (Oct 2026) · #3,649 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
48.7×
Price / book
11.8×
Free cash flow yield
-6.5%
Net margin (TTM)
-429.6%
Operating margin
-407.8%
Return on equity
-104.2%
Liabilities / assets
11.5%
Revenue growth
-4.7%
R&D / revenue
92.6%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Jan 2019: revenue $0M, net income $-3M$0MFY19Fiscal year ending Jan 2020: revenue $0M, net income $-3M$0MFY20Fiscal year ending Jan 2021: revenue $1M, net income $-3M$1MFY21Fiscal year ending Jan 2022: revenue $1M, net income $-6M$1MFY22Fiscal year ending Jan 2023: revenue $2M, net income $-4M$2MFY23Fiscal year ending Jan 2024: revenue $2M, net income $-5M$2MFY24Fiscal year ending Jan 2025: revenue $2M, net income $-10M$2MFY25Fiscal year ending Jan 2026: revenue $2M, net income $-8M$2MFY26
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Jan 2026$2M-4.7%$-8M$-8M-403.4%
Jan 2025$2M+2.4%$-10M$-10M-489.7%
Jan 2024$2M+0.5%$-5M$-5M-262.7%
Jan 2023$2M+46.5%$-4M$-4M-215.4%
Jan 2022$1M+51.1%$-6M$-6M-435.2%
Jan 2021$1M+154.1%$-3M$-3M-311.7%
Jan 2020$0M+48.0%$-2M$-3M-735.1%
Jan 2019$0M—$-3M$-3M-1332.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Jan 2026$-5M$0M$-5M$-2.58—
Jan 2025$-5M$0M$-5M$-0.99—
Jan 2024$-4M$0M$-4M$-0.69—
Jan 2023$-3M$0M$-3M$-0.53—
Jan 2022$-3M$0M$-3M$-0.80—
Jan 2021$-0M——$-0.51—
Jan 2020$-1M——$-0.50—
Jan 2019$-1M$0M$-1M$-0.62—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$2M
Net income, trailing 12 months
$-7M
RevenueNet income
Three months to Oct 2024: revenue $1M, net income $-1M$1MOct ’24Three months to Jan 2025 (from the annual report): revenue $1M, net income $-6M$1MJan ’25Three months to Apr 2025: revenue $1M, net income $-1M$1MApr ’25Three months to Jul 2025: revenue $1M, net income $-2M$1MJul ’25Three months to Oct 2025: revenue $0M, net income $-4M$0MOct ’25Three months to Jan 2026 (from the annual report): revenue $0M, net income $-1M$0MJan ’26Three months to Apr 2026: revenue $0M, net income $-1M$0MApr ’26Three months to Jul 2026: revenue $0M, net income $-1M$0MJul ’26

Latest quarter to Jul 2026: revenue $0M (-29.0% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jul 2026.

SEC filings

Official filings of Nutriband Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$2 M
Operating income
$-8 M
Net income
$-8 M

For year ending January-2026 · source: SEC filing

Balance sheet

Total assets
$8 M
Total liabilities
$1 M
Total equity
$7 M

As of January-2026

Top 19 institutional investors in Nutriband Inc.#

As of Sep 30, 2026
19 institutions held 397,514 shares (about 3.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 3.2%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 19 largest institutional investors in Nutriband Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC174,9270 (0.00%)1.44%$1 MNov 13, 2026
2Geode Capital Management, LLC66,045+3,551 (+5.68%)0.54%$0 MNov 6, 2026
3Vanguard Fiduciary Trust Co32,331+7,220 (+28.75%)0.27%$0 MNov 13, 2026
4State Street Corp24,9660 (0.00%)0.21%$0 MNov 12, 2026
5BFC Planning, Inc.18,000-1,000 (-5.26%)0.15%$0 MNov 13, 2026
6UBS Group AG17,057+16,385 (+2438.24%)0.14%$0 MNov 10, 2026
7Cetera Investment Advisers15,989New0.13%$0 MNov 13, 2026
8BlackRock, Inc.12,129+1,467 (+13.76%)0.10%$0 MNov 13, 2026
9Northern Trust Corp11,5700 (0.00%)0.10%$0 MNov 16, 2026
10Haven Private, LLC11,317-49 (-0.43%)0.09%$0 MOct 27, 2026
11Tower Research Capital LLC (TRC)3,991+1,884 (+89.42%)0.03%$0 MNov 16, 2026
12Osaic Holdings, Inc.3,100-584 (-15.85%)0.03%$0 MNov 12, 2026
13Vanguard Global Advisers, LLC2,7000 (0.00%)0.02%$0 MNov 13, 2026
14Wells Fargo & Company/mn2,6000 (0.00%)0.02%$0 MNov 16, 2026
15Jones Financial Companies Lllp4660 (0.00%)0.00%$0 MNov 13, 2026
16Citigroup Inc231New0.00%$0 MNov 4, 2026
17Farther Finance Advisors, LLC90New0.00%$0 MOct 8, 2026
18Harbour Investments, Inc.30 (0.00%)0.00%$0 MNov 9, 2026
19Caitong International Asset Management Co., Ltd2New0.00%$0 MOct 29, 2026

Mutual funds holding Nutriband Inc.#

8 funds hold shares worth $1 M (about 2.0% of the company). Since their previous reports 2 added shares and 0 sold, buying $0 M net.
Mutual funds holding Nutriband Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.122,586$0 M1.0%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.52,341$0 M0.43%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC32,875$0 M0.27%<0.01%+38%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC9,774$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors9,994$0 M0.08%<0.01%+12%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC8,237$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC7,231$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC668$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 8 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Nutriband Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
5
since
Nutriband Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Gerald GoodmanChief Financial OfficerExercise of in-the-money derivative+60,085$1.930$116 K66,085Form 5
filed Serguei MelnikChairman and President, Director, 10% ownerGift-5,000——827,999Form 4
filed Gareth SheridanCEO, Director, 10% ownerGift-10,000——1.51 MForm 4
filed Gareth SheridanCEO, Director, 10% ownerGrant or award+10,000$3.800$38 K1.52 MForm 4
filed Serguei MelnikChairman and President, DirectorBuyamended+500$4.030$2 K633,000Form 4/A
filed Serguei MelnikChairman and President, DirectorBuyamended-500$4.030$2 K633,000Form 4/A
filed Serguei MelnikChairman and President, DirectorBuy-5,000$4.030$20 K637,500Form 4
filed Serguei MelnikChairman and President, DirectorGift-10,000——632,500Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Nutriband Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
138,837
1.1% of shares · 4.91 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2025-04-30 13:34 UTC, code LUDP, resumed 13:39 UTC
  • 2025-01-22 15:13 UTC, code LUDP, resumed 15:18 UTC

Fails to deliver

  • : 689 shares at $6.49
  • : 305 shares at $5.95
  • : 750 shares at $5.97
  • : 3,418 shares at $6.00
  • : 2,693 shares at $6.27

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Nutriband Inc. scorecard#

Passes 3 of the 21 checks that could be worked out: strongest in financial health (2 of 4), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median11.8×Price to book 11.8× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median48.7×Price to sales 48.7× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-6.5%Free cash flow is -6.5% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 6
    • ✗Revenue grew in the newest year-4.7%Revenue down 4.7% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-0.7%-0.7% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-0.7%-0.7% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-2.58 vs -0.99Diluted EPS -2.58 in fiscal 2025 against -0.99 the year before (report's currency).
    • ✗Net income higher than five years earlier-$8 M-$8 M in fiscal 2025 against -$3 M in 2020.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-407.8%-407.8% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-125.5%-125.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-407.8%-407.8% in fiscal 2025 against -215.4% in 2022.
  • Financial health2 of 4
    • ✓Short-term assets cover short-term liabilities6.4×Current ratio 6.40 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-416.0×Operating income -416.0 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone43.05Z-score 43.05 (safe zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year9.8%Diluted shares up 9.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Nutriband Inc.'s statements, beside the median of Biotechnology.

Nutriband Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-407.8%-60.5%
Net margin-403.4%-68.9%
Return on equity-125.6%-61.0%
Revenue growth, 3 years a year-0.7%12.9%
Revenue growth-4.7%15.8%
Free cash flow margin-252.0%-61.5%

3of 8on the Piotroski tests of financial strength

  • Revenue fell 4.7% against the year before.
  • Net loss of $8 million, the 10th loss-making year in a row.
  • Free cash flow was negative: -$5 million.
  • The share count rose 9.8% in the year.

Nutriband Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Nutriband Inc.: statements by fiscal year
PeriodTrendFY 2025to Jan 31, 2026FY 2024to Jan 31, 2025FY 2023to Jan 31, 2024FY 2022to Jan 31, 2023FY 2021to Jan 31, 2022FY 2020to Jan 31, 2021FY 2019to Jan 31, 2020FY 2018to Jan 31, 2019FY 2017to Jan 31, 2018FY 2016to Jan 31, 2017
Income statement
Revenue2,0372,1402,0852,0801,422944371245——
Cost of revenue1,4701,3961,2231,329918627r549288——
Gross profit566743862750554316————
Research and development1,8913,1191,960982411—————
Selling, general and administrative6,9934,3143,7743,9164,0232,912r1,7913,288172151
Operating expenses8,88411,0285,734—6,6152,9122,3403,5772,672—
Total costs and expenses10,35512,4246,9576,5557,5333,5402,340—2,672151
Operating income−8,318−10,285−4,872−4,475−6,111−2,596−1,969−3,331−2,672−151
Interest and finance income11119217———————
Interest expense and finance costs2321768.3118281r73———
Other non-operating income (expense)88−198−6135,2266,615r−337−752———
Income before tax−8,230−10,483−5,485−4,483−6,176−2,933−2,722−3,331−2,672—
Income from continuing operations−1,728−2,201r1,152r−942r1,297—————
Net income including minority interests————−6,176−2,933−2,767r−3,331−2,672−151
Net income attributable to shareholders−8,230−10,483−5,485−4,483−6,176−2,933−2,722−3,331−2,672−151
Earnings per share, basic-2.58-0.99-0.69-0.53-0.80r-0.51-0.50-0.62r-0.14-0.01
Earnings per share, diluted-2.58-0.99-0.69-0.53-0.80-0.51-0.50-0.62r-0.14-0.01
Shares, weighted average (basic)12118.08.57.9—————
Shares, weighted average (diluted)12118.08.57.9r5.85.45.4r1921
Balance sheet
Cash and cash equivalents4,5754,3124931,9854,89215210475—27
Receivables11874149113711091313——
Inventory11821216922913253——4.18.0
Current assets4,9894,7941,0222,6945,4653144359016538
Loans to customers (net)————122—————
Property, plant and equipment5676957758989791,077111146146—
Right-of-use (leased) assets72—316319—9.6———
Goodwill1,7201,7205,0225,0225,3497,5301,7191,719——
Other intangible assets2002616677809271,007r287r296r——
Non-current assets——————2,155———
Total assets7,5487,4707,5179,45612,7409,9272,1982,80816538
Accounts payable503699680535640941772292124.1
Customer deposits———250250—————
Debt due within a year——2,000————01.8r1.8r
Current liabilities7849839997497792,5692,0224034315
Lease liabilities (non-current)48——34——————
Total liabilities8681,0411,0798838802,8152,022——15
Retained earnings−46,692−38,463−27,980−22,495−18,011−11,835−8,902−6,181−2,849−177
Shareholders' equity6,6796,4296,4388,57311,8597,1121752,40512223
Total liabilities and equity7,5487,4707,5179,45612,7409,9272,1982,80816538
Shares outstanding12r11r8.9r7.89.2r6.3r5.45.4r2116
Cash-flow statement
Depreciation and amortization1942852883303091607237——
Share-based compensation2,6341,4095007323652,0052531,764—7.8
Cash from operating activities−5,135−4,627−3,528−2,987−2,809−297−894−1,105−93−148
Capital expenditure−5.3−92−52−79−82——−4.2——
Cash from investing activities−5.3−92−52−79−8267—−404——
Debt issued——107———250———
Debt repaid—————−339————
Shares issued5,3068,407r——583515—1,50050175
Cash from financing activities5,4038,5372,0871607,6313724301,98466175
Exchange-rate effect on cash——————−0.30.4−0.00.0
Change in cash————4,740142−464475−2727
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jul 31, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Nutriband Inc. sells: revenue by product line, fiscal 2026#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Sale of Goods$2 M100%

Business segments

  • Pocono Pharmaceuticals$2 M100%

Countries and regions

Source: SEC annual report (XBRL data) · as of Jan 31, 2026

Events at Nutriband Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 1 · Material agreement 2 · Unregistered share sale 4 · Bylaws or fiscal year changed 2 · Shareholder vote 3

Nutriband Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreement8-K
Shareholder vote8-K
Unregistered share saleBylaws or fiscal year changed8-K
Bylaws or fiscal year changed8-K
Shareholder vote8-K
Unregistered share sale8-K/A
Unregistered share sale8-K
Directors and officers8-K
Material agreement8-K
Unregistered share sale8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Jun 22, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Nutriband Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2018$1 MNo. 1Under $2 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Nutriband Inc.#

1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $58 K a year.

Certified, FY2025
1
#1,980 among companies on value.today
Worker positions
1
Median wage offered
$58 K
a year, full-time
Applications filed
1
Nutriband Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Internal Control SpecialistEconomists1$58 K

Where: Orlando, FL 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Nutriband, Inc.

How Nutriband Inc. compares in Biotechnology

  • Market cap$79 M · higher than 33% of 726
  • Revenue$2 M · higher than 30% of 647
  • Net margin-429.6% · higher than 15% of 408
  • Revenue growth-4.7% · higher than 39% of 438
  • Price / sales48.7× · lower than 18% of 339
  • Price / book11.8× · lower than 13% of 534
  • FCF yield-6.5% · higher than 66% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Nutriband Inc.🇺🇸$79 M—-429.6%-4.7%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending January-2026
Balance sheet:
As of January-2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Nutriband Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Nutriband Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Nutriband Inc.? Suggest a correction